Literature DB >> 1796130

Mood responses of remitted schizophrenics to methylphenidate infusion.

D Robinson1, D Mayerhoff, J Alvir, T Cooper, J Lieberman.   

Abstract

To investigate the mood response of schizophrenic subjects to psychostimulant challenge, 29 neuroleptic-treated subjects (22 with schizophrenia and 7 with schizoaffective disorder) in clinical remission received two infusions, one with methylphenidate 0.5 mg/kg and the other with normal saline, under double-blind conditions. Twenty-five of these subjects were withdrawn from neuroleptics and given a second set of double-blind infusions. Infusion mood responses were classified as euphoric, neutral, mixed or dysphoric. Subjects were also rated as either psychotic symptom activators to the infusion or no change in psychotic symptoms. Overall response by mood category was as follows: 35.2% euphoric, 50% neutral, 5.6% mixed and 9.3% dysphoric. Mood responses were not correlated with sex, methylphenidate plasma levels or diagnostic distinctions between schizophrenia and schizoaffective disorder. Although they occurred infrequently, dysphoric and mixed mood responses were associated with high rates of psychotic activation. Comparing subjects on and off neuroleptics, subjects on neuroleptics had more euphoric responses than the same subjects off neuroleptics. This increased number of euphoric responses in subjects taking neuroleptics compared to off neuroleptics suggests that neuroleptic treatment status may be an important factor in assessing psychostimulant use in schizophrenia patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1796130     DOI: 10.1007/BF02244317

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Blockade by reserpine of methylphenidate-induced release of brain dopamine.

Authors:  C C Chiueh; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1975-05       Impact factor: 4.030

2.  Psychologic and neuroendocrine response to methylphenidate.

Authors:  W A Brown
Journal:  Arch Gen Psychiatry       Date:  1977-09

Review 3.  Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs.

Authors:  P M Groves; G V Rebec
Journal:  Annu Rev Psychol       Date:  1976       Impact factor: 24.137

4.  Dextroamphetamine. Evaluation of psychomimetic properties in man.

Authors:  J D Griffith; J Cavanaugh; J Held; J A Oates
Journal:  Arch Gen Psychiatry       Date:  1972-02

5.  Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

6.  Haloperidol and lithium blocking of the mood response to intravenous methylphenidate.

Authors:  D Wald; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

7.  D-amphetamine-induced release of "newly synthesized" and "stored" dopamine from the caudate nucleus in vivo.

Authors:  C C Chiueh; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

8.  Endocrine and behavioural responses to methylphenidate in depression.

Authors:  P R Joyce; R A Donald; M G Nicholls; J H Livesey; R M Abbott
Journal:  Psychol Med       Date:  1986-08       Impact factor: 7.723

9.  A new distinction between the euphoric and the anti-depressant effects of methylamphetamine.

Authors:  S A Checkley
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

10.  A sensitive gas chromatographic method for the determination of methylphenidate (Ritalin) and its major metabolite alpha-phenyl-2-piperidine acetic acid (ritalinic acid) in human plasma using nitrogen-phosphorous detector.

Authors:  B L Hungund; M Hanna; B G Winsberg
Journal:  Commun Psychopharmacol       Date:  1978
View more
  3 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 3.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.